Covid-19 therapy could come by end of year, vaccine in 2021
Electron microscope image of Covid-19 (yellow) emerging from the surface of cells (blue/pink) cultured in a US lab
Keystone / Niaid- Rml/national Institutes O
Swiss pharma and business insiders predict that an effective drug therapy against Covid-19 will be available by the end of this year, but a vaccine might take a year longer than that.
This content was published on
2 minutes
Keystone-SDA/swissinfo.ch/sm
Português
pt
Tratamento para coronavírus pode chegar no final do ano, vacina em 2021
“In the best-case scenario, a drug could be available before the end of 2020,” said on Monday Francesco De Rubertis, director and co-founder of Medicxi, a Geneva-based venture capital company that invests in biotechnology.
In an interview with the Swiss newspaper Le TempsExternal link, De Rubertis said, “We should know by the end of 2020 if any of the vaccines tested are promising. If the answer is positive, a vaccine may appear in the second half of 2021, possibly in the third quarter.”
He noted that this time frame would be “exceptionally short” – less than two years after the appearance of Covid-19 – when it normally takes five to seven years to develop a vaccine. De Rubertis predicts that a vaccine will come from a large pharma or a large biotech company rather than a start-up.
Spring 2021?
Meanwhile, the chairman of the board of the Swiss reinsurance company Swiss Re reckons a vaccine will be ready “in the first quarter of 2021 at the earliest – and then it will have to go into mass production very quickly”. In an interview published by the CH-Media newspaper group on Tuesday, Walter Kielholz said that the world would not return to normal until there was a vaccine against Covid-19.
However, he said he could imagine lockdown measures being relaxed soon. “Why jewellery shops or furniture stores, for example, have to remain closed is beyond me. They could resume operations if the hygiene regulations were observed. This also applies to other shops, such as clothing stores,” he said.
During a briefing on Tuesday, Margaret Harris of the Geneva-based World Health OrganizationExternal link said, “We shouldn’t really be expecting to see the vaccine for 12 months or longer.”
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
This story has been amended to clarify that Francesco De Reubertis predicts a drug therapy will be available by the end of 2020, and a vaccine in 2021.
Popular Stories
More
Foreign affairs
What Trump’s return or a new Harris administration would mean for Switzerland
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
COP29: Swiss NGOs call for strong financial support
This content was published on
Ahead of COP29, Swiss NGOs call for wealthy nations to pay $1,000 billion a year to help other countries solve climate problems.
Real Swiss wages likely to rise in 2025, says UBS bank
This content was published on
Higher wages and falling inflation are likely to boost Swiss purchasing power, which will be dragged back by rising health premiums.
This content was published on
Switzerland has a new tectonic map at a scale of 1:500,000, containing updates to geometry, distribution and nomenclature of the tectonic units.
This content was published on
Swiss artist Daniel Spoerri, known for his artworks using leftover food with dirty cutlery and crockery, has passed away in Vienna at the age of 94.
Climate change tipped to alter Swiss avalanche patterns by 2100
This content was published on
Climate change is expected to result in fewer avalanches overall in Switzerland but to increase the danger of wet snow avalanches by 2100.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Start-up firms feel frozen out of coronavirus bailout funds
This content was published on
Start-ups are falling through the cracks of a state-sponsored funding scheme designed to keep companies afloat during the coronavirus crisis.
With no prospects for profits, big pharma neglects new infectious diseases
This content was published on
More companies are shifting resources away from emerging infectious diseases into more lucrative areas like cancer. What does this mean for Covid-19?
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.